Key Highlights
- Calendars conflict on the third-quarter 2026 report date, showing November 19 and November 26, 2026; no company notice was found, and last year's report came on November 20, 2025.
- The calendar lists an EPS estimate of a USD 0.15 loss per share, which is unverified; the first-half 2026 net loss was USD 68.8 million, or USD 0.76 per share, against USD 18.8 million, or USD 0.25.
- Cash, short-term and restricted deposits were USD 104.8 million at June 30, 2026, up from USD 76.9 million at year-end 2025, while first-half research spending rose to USD 20.9 million from USD 14.2 million.
- A Tolmar collaboration for US prostate rights brings a USD 20 million Equity investment, USD 15 million toward a production Facility and milestones up to USD 96.5 million for the initial indication.
Two Dates and an Unverified Loss Estimate
Alpha Tau Medical (NASDAQ:DRTS) is listed for third-quarter 2026 results on November 19, 2026 on one calendar, while another lists November 26, 2026 after the close. No company announcement of either date was found, so the date is unconfirmed. The company, an Israeli developer of the Alpha DaRT localized radiation device for solid tumors, reported its third quarter on November 20, 2025. The calendar's EPS estimate is a USD 0.15 loss per share, with no basis stated, and no published Revenue consensus was found. For a company still running clinical studies, analyst estimates can be sparse, so the reaction often turns on milestones and cash rather than the EPS gap.
First-Half Loss Inflated by Warrant Remeasurement
The second-quarter release in August 2026 gave first-half figures: a net loss of USD 68.8 million, or USD 0.76 per share, with USD 41.4 million of net financial expenses mainly from remeasuring warrant liabilities as the share and warrant prices rose. That item is non-cash, and it can swing sharply in either direction. Research spending was USD 20.9 million, driven by compensation, trial activity and raw material purchases, general and administrative USD 5.7 million and Marketing USD 0.6 million. A consensus comparison for that quarter and the share price reaction were not verified, so no beat or miss is stated, and the release extract disclosed no cash runway.
Trial Milestones That Matter More Than the Per-Share Loss
Management listed several near-term events. Recruitment in the IMPACT pancreatic study is due to finish in the third quarter, with initial data late 2026 or early 2027, and the REGAIN glioblastoma study, where the FDA cleared enrollment of the final seven patients, expects more data around year-end. ReSTART, a skin cancer study with 88 patients enrolled and Breakthrough Device Designation, targets top-line data in the same window, and a first US prostate patient is expected in the second half. The Tolmar deal also carries up to USD 65 million of commercial milestones. A slip in any timeline, a change in cash burn or a swing in warrant value would be read as a miss; on-time progress would count as a beat.
Where Things Stand
It depends, because neither the date nor the result is confirmed. Alpha Tau Medical (NASDAQ:DRTS) holds USD 104.8 million of cash against roughly USD 27.2 million of first-half operating costs (calculated from three reported lines), and a partner deal adds funding and milestone potential. Reported losses can be distorted by warrant values. Next markers are a company confirmation of the report date, cash versus June 30, the IMPACT recruitment update and the late 2026 data readouts.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...